Cubist Pharmaceuticals has initiated the dosing in a Phase II study of ecallantide, a drug designed to attract and block the plasma kallikrein enzyme linked to blood loss during on-pump cardiothoracic surgery. The company also is undertaking Phase I studies on Clostridium difficile-associated diarrhea and multidrug resistant Gram-negative infections.

Related Summaries